BMY
Bristol-Myers Squibb Company
- Healthcare
- US companies in Drug Manufacturers - General (9)
- NYSE · USD
- Mkt cap $125.7bn
$61.55
as of 27 Oct 2026, 10% below its 52-week high
Screens as well placed to keep growing its dividend, with low cut-risk signals.
These scores are a resilience check on the dividend, not a recommendation to buy or sell. They are not financial advice.
- Trailing yield
- 4.09%Last 12 months of regular payments at today's price
- Forward yield
- 4.09%Each payment expected in the next 12 months, not the latest one doubled
- Earnings cover
- 1.8×Pays 55% of earnings
- Cash cover
- 2.2×Free cash flow over dividends paid
- 5y dividend growth
- +6.6% a yearLast cut in FY2016
- Next ex-dividend date
- Estimated2 Jan 2027Quarterly dividend of about $0.63
Compared with US companies in Drug Manufacturers - General (9)
- Trailing yield is higher than 7 of the 8 other US companies in Drug Manufacturers - General.
- 5y dividend growth (as paid) is higher than 4 of the 7 other US companies in Drug Manufacturers - General with a 5y growth figure.
Quality
81
HighCapacity to keep growing the dividend
Risk
25
LowSignals of dividend-cut pressure
Trim
42
LowHow extended the valuation looks
Why Risk is 25
BMY against US companies in Drug Manufacturers - General (9)
Valuation against its own history
As of the last reported period (30 Jun 2026). P80 means the figure is higher than 80% of BMY’s past readings.
- P/E12.7×P4, good for this measure
- Yield4.34%P82, good for this measure
- FCF payout44.5%P90, poor for this measure
- Net debt / EBITDA2.05P56, neutral for this measure
- DGR 5y+5.9%P55, neutral for this measure
- ROIC15.2%P89, good for this measure
Forecast your income with the BMY dividend calculator
Inspect surfaces history; it does not predict the future. Nothing here is financial advice or an instruction to buy or sell. Always do your own research. See the Terms of Service.